Trial Profile
Nerve Growth Factor Eye Drops as a Novel Treatment for Vision Loss in Patients With Retinitis Pigmentosa: From Preclinical to Clinical Phase II Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Cenegermin (Primary)
- Indications Retinitis pigmentosa
- Focus Therapeutic Use
- Acronyms NEMO
- 02 Sep 2017 Status changed from active, no longer recruiting to completed.
- 01 Feb 2016 Planned end date changed from 1 Jan 2017 to 1 Feb 2017, as reported by ClinicalTrials.gov.
- 01 Feb 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2017, as reported by ClinicalTrials.gov.